about
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowChemistry and biology of diazonamide A: second total synthesis and biological investigationsFunctional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic deviceERG induces taxane resistance in castration-resistant prostate cancerThe beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).β-1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Targeting microtubules for cancer chemotherapy.Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.The importance of p53 location: nuclear or cytoplasmic zip code?Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Exploitation of the HIF axis for cancer therapy.Isolation and characterization of circulating tumor cells in prostate cancer.EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analoguesHFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.Syntheses and biological activities of novel 2-methoxyestradiol analogs, 2-fluoroethoxyestradiol and 2-fluoropropanoxyestradiol, and a radiosynthesis of 2-[(18)F]fluoroethoxyestradiol for positron emission tomography.A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation.Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues.Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol).The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression.The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.Discovery of a biologically active thiostrepton fragment.Studies toward diazonamide A: development of a hetero-pinacol macrocyclization cascade for the construction of the bis-macrocyclic framework of the originally proposed structure.Molecular design and chemical synthesis of a highly potent epothilone.Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.Integrating image analysis algorithms in a web interface for the quantification of microtubule dynamics.Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress.Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.CENP-E checks in microtubule-drug resistance.Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agentsDesign, synthesis, and biological properties of highly potent epothilone B analoguesCombinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic scheduleSynthesis and biological evaluation of 12,13-cyclopropyl and 12,13-cyclobutyl epothilones
P50
Q27334142-96DE9EAF-1930-449C-BBCC-14271BB150ACQ28286450-FEB147DD-C881-4D59-B5AF-85CA312A3890Q28482878-A493803E-A45B-4AB4-98C1-504E408C3EB0Q30602046-B8FAA1A2-C0E9-435E-B9C6-81B35629D2DEQ33404408-BF595904-8077-424D-B928-B41303E7E425Q33419433-F075BC89-0D48-476D-BE25-CF3935B62F91Q34108738-1C0CA684-E0D7-4D95-A751-0F1E0C4D60C6Q34395830-294A1461-2BDC-4B91-AB54-039259A96DE8Q34541981-3BC52808-BFD6-47B2-9803-4A1B2B3E5EA9Q35639326-3E46C0C6-4BBF-48B1-83FB-694CDBC135C8Q35774561-47C56204-3619-4898-BECD-4E3791366AEAQ35805307-FC8E05D8-29A2-4955-B29F-7FD0224D7672Q36310363-6D284C30-390B-4F7B-A81A-FCB6FAA8CC4CQ36950656-8CDB08D7-D511-43B8-AC83-53B5AEFFA2F6Q36979015-F794F7D8-918B-419C-919D-EF68DA7FF7B1Q37069841-8633847E-3BA9-46DC-9E6F-CA6E13ED99ABQ37119737-95758ACE-25B1-4BAE-8402-9298CEB13B42Q37172880-87E74F6F-B04F-437A-90F0-857F1452F848Q40421501-0F20FC19-E468-4E6F-BA22-4AF59258AF1EQ40609131-8A651E0E-BBE7-4988-B1AB-7FD42625B29BQ40765807-CDD6B0CB-22A7-4A3B-9E9F-82A7F28CD9CEQ40779922-5DB798DE-779B-4BF9-817D-25AE93FDE455Q41009979-9F74364B-006F-488D-B1EF-CF734B2AED1FQ43245330-7116B293-E4C8-4770-A8D4-D896565BF844Q44064731-DDE5D21A-8D0D-4919-A108-6E119889B490Q44426540-5722637E-481E-48FC-8383-889811155B24Q44984621-26F8A1A8-FA25-4D71-B953-FC7D5C7408F1Q45964621-456D2F05-2CF8-47F6-A0C7-73F26E8F8D40Q46063741-DC82EDAC-824D-4DFF-863D-065D312B7D0FQ46844661-BD999D6B-F637-45CD-B280-E68C8A6BF582Q46852859-33A8C17D-B6A4-48AA-9784-6482BC22B808Q48764311-F693CE97-5EE3-4A6E-8B34-448E5C2243D1Q50623365-7B7706FE-57A2-4D85-86D9-CBE38A294D14Q52826331-9ECD78D2-F3BE-4969-A5B3-8114C5FDE750Q54678137-905E5887-F93A-4513-8623-0F0F9221E02BQ73502599-BCFF026C-8182-43D8-8AAE-14FA5F5BF859Q73758737-6B5C7D31-A20E-426D-950C-20A4A423559AQ74029738-A9A950D1-79BD-47E2-9F86-0A3F515A3853Q77596694-A520AA5C-585A-4155-A0F2-CC904BA91AE6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paraskevi Giannakakou
@ast
Paraskevi Giannakakou
@en
Paraskevi Giannakakou
@es
Paraskevi Giannakakou
@nl
Paraskevi Giannakakou
@sl
type
label
Paraskevi Giannakakou
@ast
Paraskevi Giannakakou
@en
Paraskevi Giannakakou
@es
Paraskevi Giannakakou
@nl
Paraskevi Giannakakou
@sl
prefLabel
Paraskevi Giannakakou
@ast
Paraskevi Giannakakou
@en
Paraskevi Giannakakou
@es
Paraskevi Giannakakou
@nl
Paraskevi Giannakakou
@sl
P106
P21
P31
P496
0000-0001-7378-262X
P569
2000-01-01T00:00:00Z